United States Artificial Organs Market By Organ Type (Artificial Heart {Prosthetic Heart Valves, Ventricular Assist Devices, Cardiac Pacemakers}, Artificial Kidney, Artificial Pancreas, Artificial Lungs, Cochlear Implants, Others), By Technology (Electronic Bionics, Mechanical), By Type of Fixation (Wearable, Implantable), By Material Type (Silicon, Plastic, Steel), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 5.44 Billion
CAGR (2026-2031)	7.32%
Fastest Growing Segment	Artificial Kidney
Largest Market	West
Market Size (2031)	USD 8.31 Billion

Market Overview

The United States Artificial Organs Market will grow from USD 5.44 Billion in 2025 to USD 8.31 Billion by 2031 at a 7.32% CAGR. The United States Artificial Organs Market comprises engineered devices designed to replace or assist the function of failed biological organs, integrating with living tissue to restore physiological capabilities. Market growth is primarily driven by the escalating prevalence of end-stage organ failure resulting from chronic conditions such as diabetes and cardiovascular diseases. Further impetus stems from the persistent national shortage of suitable donor organs and continuous advancements in biomaterials and medical device engineering, enhancing device functionality, durability, and biocompatibility.

A significant challenge impeding market expansion is the substantial cost associated with the extensive research, development, manufacturing, and complex regulatory approval processes for these critical devices. According to the Association of Organ Procurement Organizations (AOPO), based on OPTN data as of January 29, 2026, more than 100,000 people were waiting for a life-saving organ transplant in the United States, underscoring the considerable unmet demand that artificial organs aim to address despite these financial and regulatory hurdles.

Key Market Drivers

Donor Shortage Drives the Artificial Organs Market
The critical shortage of donor organs significantly propels the United States Artificial Organs Market. With the supply of compatible donor organs consistently failing to meet the demand for transplantation, artificial alternatives become essential solutions for patients facing end-stage organ failure. This persistent imbalance places immense pressure on the healthcare system to adopt and refine engineered organ replacements. For example, according to the United Network for Organ Sharing (UNOS), January 2026, more than 90,000 Americans were still waiting for a lifesaving kidney transplant. This substantial unmet need drives continuous investment and development in devices such as artificial kidneys and ventricular assist devices, which can extend patient lives and improve quality of life while awaiting a suitable donor, or as a permanent solution.

Technological Innovation and AI Accelerate Adoption of Artificial Organs
Advancements in medical technology and biomedical engineering represent another pivotal driver for market expansion. Continuous innovations in biomaterials, miniaturization, surgical techniques, and integration of artificial intelligence (AI) are enhancing the functionality, durability, and biocompatibility of artificial organs. These technological improvements lead to safer, more effective devices with fewer complications, increasing their clinical acceptance and utility. This progress is evident in regulatory activities; according to Censinet, June 2026, by early 2026, the FDA had cleared or approved over 1,000 AI/ML medical devices, many of which can enhance the precision and performance of artificial organ systems. These innovations are crucial for addressing the high demand for organ replacement solutions; according to the United Network for Organ Sharing, in 2025, 49,064 organ transplants were performed nationwide, demonstrating the scale of intervention required in the organ replacement landscape.

Download Free Sample Report

Key Market Challenges

High Costs and Regulatory Barriers Impede Market Expansion
The substantial cost associated with extensive research, development, manufacturing, and complex regulatory approval processes represents a critical impediment to the expansion of the United States Artificial Organs Market. Developing these engineered devices demands considerable upfront financial outlay due to intricate design, advanced biomaterials, and rigorous testing requirements for safety and efficacy. These significant investments are essential for creating devices that integrate with living tissue and restore physiological capabilities, but they also create high financial barriers to market entry and expansion.

R&D Investment and Regulatory Delays Limit Market Access
This financial burden is further exemplified by the substantial commitment to innovation within the broader medical technology sector. According to the Advanced Medical Technology Association (AdvaMed), in 2024, total research and development expenditures by U.S. medtech firms were at least $22.6 billion. Such immense spending, particularly for highly complex devices like artificial organs, limits the number of companies able to participate and innovate, thereby slowing market development. The protracted and costly regulatory approval process for these devices, involving extensive clinical trials and stringent documentation, also contributes significantly to overall expenses, further restricting market accessibility for new and existing artificial organ technologies.

Key Market Trends

Personalized 3D bioprinting for immune-matched organs
The emergence of 3D bioprinting for personalized organ fabrication represents a transformative trend within the United States Artificial Organs Market, shifting the paradigm from generic replacements to patient-specific solutions. This technology enables the precise construction of organs using a patient's own cells, significantly mitigating the risk of immune rejection and eliminating the need for lifelong immunosuppressive drug regimens. Such advancements streamline post-transplant care and improve long-term patient outcomes by ensuring optimal compatibility and functionality for each individual. According to the Advanced Research Projects Agency for Health (ARPA-H), in the January 2026 article "ARPA-H awards teams set to bioprint universally matched organs on demand", its Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program has allocated up to $176.8 million over five years to support research and development in bioprinting personalized, immune-matched organs.

Development of biohybrid and bioartificial organs
Another pivotal trend is the accelerated development of biohybrid and fully bioartificial organs, aiming to integrate living biological components with engineered structures to closely replicate natural physiological functions. These sophisticated devices transcend purely mechanical assistance by providing active biological processes, offering more holistic and durable solutions for end-stage organ failure. This approach minimizes complications associated with purely synthetic implants and enhances the overall efficacy and longevity of artificial organs. For instance, according to Seeking Alpha, in its April 2026 article "United Therapeutics: The Future Lies With Manufactured Organs", United Therapeutics completed a Phase 1 study in early 2026 for miroliverELAP, an external bioengineered liver assist product designed for patients with acute liver failure, with Phase 2 expected to commence later in the year.

Segmental Insights

Growth Drivers and Regulatory Support for the U.S. Artificial Kidney Market
The Artificial Kidney segment represents a key growth driver within the United States Artificial Organs Market. This rapid expansion is primarily fueled by the escalating prevalence of End-Stage Renal Disease (ESRD) and Chronic Kidney Disease, driven by factors such as aging demographics, diabetes, and hypertension, which collectively create a substantial and growing patient population requiring renal replacement therapies. Concurrently, a critical and persistent shortage of compatible donor kidneys intensifies the demand for viable artificial alternatives. Technological advancements in miniaturized, portable, and implantable artificial kidney systems, alongside favorable regulatory support from entities like the FDA's Breakthrough Device Program and initiatives such as the KidneyX, are further accelerating innovation and commercialization, promoting more accessible and patient-centric care models, including home-based dialysis.

Regional Insights

West Region: Leadership Driven by Infrastructure, Centers, and Innovation
The West stands out as a prominent region within the United States Artificial Organs Market. This leadership is primarily attributed to the significant concentration of advanced cardiac care infrastructure, which is crucial for the implementation and management of artificial organ technologies. Furthermore, the region benefits from the presence of major transplant centers and robust procedural volume capabilities, facilitating high adoption rates and extensive clinical experience with artificial organs. The West also actively supports ongoing clinical studies and advanced device-integration programs, fostering innovation and the early adoption of next-generation artificial organ solutions. These factors collectively contribute to the region's strong position in the market.

Recent Developments

• In April 2025, Carmat, a developer of advanced total artificial hearts, received conditional approval from the U.S. Food and Drug Administration to advance its early feasibility study for the Aeson artificial heart in the United States. This authorization allows Carmat to commence recruitment for the second cohort of the study, which involves patients eligible for heart transplantation. This milestone represents a key step in Carmat's strategy to introduce its therapeutic alternative for individuals with advanced biventricular heart failure into the American market, anticipating potential commercial launch as early as 2028.
• In December 2024, United Therapeutics Corporation announced a breakthrough in xenotransplantation within the United States artificial organs market. The company successfully performed the world's first transplant of its UKidney, a genetically modified pig kidney, into a living human recipient on November 25, 2024. This event marked a crucial step in United Therapeutics' broader efforts in organ manufacturing, which include xenotransplantation, regenerative medicine, and 3D organ bioprinting. The achievement aims to address the critical shortage of transplantable organs, particularly kidneys, for patients with end-stage organ disease.
• In October 2024, Johnson & Johnson MedTech's Abiomed division announced a significant advancement in the United States artificial organs market. The company's compressible, expandable heart pump, the Impella ECP, successfully completed its pivotal clinical trial. This development positioned the device for an upcoming review by the U.S. Food and Drug Administration. Described as the world's smallest heart pump, the Impella ECP is designed to shrink for easier insertion before expanding to full pumping strength within the heart, offering a new option for patients requiring temporary circulatory support during high-risk cardiac interventions.
• In August 2024, researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering made a breakthrough in bioprinting for artificial organs. The team developed a novel method to 3D print vascular networks featuring interconnected blood vessels with distinct smooth muscle and endothelial cell layers. This innovative vascular architecture closely replicates natural blood vessels, representing substantial progress toward manufacturing implantable human organs. This research significantly advances the field by providing a more robust foundation for creating functional, lab-grown tissues for therapeutic applications in the United States.

Key Market Players

• B. Braun Medical, Inc.
• Abiomed, Inc.
• Baxter International, Inc.
• Jarvik Heart, Inc.
• Medtronic, Inc.
• HeartWare International, Inc.
• SynCardia Systems, LLC
• Boston Scientific Corporation
• Terumo Medical Corporation
• Edwards Lifesciences Corporation

By Organ Type	By Technology	By Type of Fixation	By Material Type	By Region
Artificial Heart {Prosthetic Heart Valves Ventricular Assist Devices Cardiac Pacemakers} Artificial Kidney Artificial Pancreas Artificial Lungs Cochlear Implants Others	Electronic Bionics Mechanical	Wearable Implantable	Silicon Plastic Steel	Northeast Midwest South West

Report Scope:

In this report, the United States Artificial Organs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Artificial Organs Market, By Organ Type:

• Artificial Heart {Prosthetic Heart Valves
• Ventricular Assist Devices
• Cardiac Pacemakers}
• Artificial Kidney
• Artificial Pancreas
• Artificial Lungs
• Cochlear Implants
• Others

• United States Artificial Organs Market, By Technology:

• Electronic Bionics
• Mechanical

• United States Artificial Organs Market, By Type of Fixation:

• Wearable
• Implantable

• United States Artificial Organs Market, By Material Type:

• Silicon
• Plastic
• Steel

• United States Artificial Organs Market, By Region:

• Northeast
• Midwest
• South
• West